Met receptor juxtamembrane exon 14 alternative spliced variant: Novel cancer genomic predictive biomarker

Patrick C. Ma

doi:10.1158/2159-8290.CD-15-0769

Met receptor juxtamembrane exon 14 alternative spliced variant: Novel cancer genomic predictive biomarker

Patrick C. Ma

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Summary: Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal MET ex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy.

Original language	English (US)
Pages (from-to)	802-805
Number of pages	4
Journal	Cancer Discovery
Volume	5
Issue number	8
DOIs	https://doi.org/10.1158/2159-8290.CD-15-0769
State	Published - Aug 1 2015

All Science Journal Classification (ASJC) codes

Oncology

Access to Document

10.1158/2159-8290.CD-15-0769

Cite this

@article{fd23566f255d4e269caefaf582cbd6a0,

title = "Met receptor juxtamembrane exon 14 alternative spliced variant: Novel cancer genomic predictive biomarker",

abstract = "Summary: Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal MET ex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy.",

author = "Ma, {Patrick C.}",

note = "Publisher Copyright: {\textcopyright} 2015 American Association for Cancer Research.",

year = "2015",

month = aug,

day = "1",

doi = "10.1158/2159-8290.CD-15-0769",

language = "English (US)",

volume = "5",

pages = "802--805",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "8",

}

TY - JOUR

T1 - Met receptor juxtamembrane exon 14 alternative spliced variant

T2 - Novel cancer genomic predictive biomarker

AU - Ma, Patrick C.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Summary: Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal MET ex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy.

AB - Summary: Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal MET ex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84939204199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939204199&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-15-0769

DO - 10.1158/2159-8290.CD-15-0769

M3 - Article

C2 - 26243862

AN - SCOPUS:84939204199

SN - 2159-8274

VL - 5

SP - 802

EP - 805

JO - Cancer Discovery

JF - Cancer Discovery

IS - 8

ER -

Met receptor juxtamembrane exon 14 alternative spliced variant: Novel cancer genomic predictive biomarker

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this